LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.27 USD -1.55% Market Closed
Market Cap: 33.4m USD

EV/EBIT
Enterprise Value to EBIT

1.4
Current
1
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
1.4
=
Enterprise Value
-39.6m USD
/
EBIT
-28m USD
Market Cap EV/EBIT
NL
LAVA Therapeutics NV
NASDAQ:LVTX
33.4m USD 1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -209 183.8
US
Abbvie Inc
NYSE:ABBV
369.9B USD 25.7
US
Amgen Inc
NASDAQ:AMGN
167.3B USD 29.2
US
Gilead Sciences Inc
NASDAQ:GILD
139.6B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.6B USD 26.6
US
Epizyme Inc
F:EPE
94.1B EUR -519.7
AU
CSL Ltd
ASX:CSL
121.8B AUD 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.5B USD 11.3
US
Seagen Inc
F:SGT
39.3B EUR -55.1
NL
argenx SE
XBRU:ARGX
32.6B EUR -2 300.8
EBIT Growth EV/EBIT to Growth
NL
LAVA Therapeutics NV
NASDAQ:LVTX
Average EV/EBIT: 18.6
1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 183.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.7
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.2
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 300.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
1.2
2-Years Forward
EV/EBIT
1
3-Years Forward
EV/EBIT
0.8